Wendy W Lane, MD
Internal Medicine · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Permanente Medical Group Inc · 10,928 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lane’s office at (408) 851-1000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A62103 · Current
Licensed to practise in California · since 1997 · expires 2028-08-31 · Hahnemann University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$15,249
Pharmacies billed $15,249 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (18 of 276) in 2024. A higher opioid share than 9 in 10 peers; the typical internal medicine clinician is at 1%.
246 generic and fewer than 11 brand-name prescriptions · $15,249 in drug cost · 17 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ropinirole | 17 | $226 | $13 |
| Metoprolol | 14 | $171 | $12 |
| Amlodipine Besylate | 12 | $136 | $11 |
| Atorvastatin | 11 | $110 | $10 |
| Oxycodone | 11 | $84 | $8 |
Year by year
| 2024 | 276 | 85 | 7% (18) | None | $15,249 |
| 2023 | 315 | 90 | 4% (11) | 18% | $33,803 |
| 2022 | 290 | 91 | 6% (17) | None | $13,882 |
| 2021 | 173 | 69 | None | 16% | $13,989 |
| 2020 | 215 | 76 | 6% (12) | None | $13,702 |
| 2019 | 227 | 97 | None | None | $9,037 |
| 2018 | 233 | 93 | None | None | $6,876 |
| 2017 | 241 | 91 | None | 26% | $9,469 |
| 2016 | 350 | 121 | 5% (17) | None | $16,541 |
| 2015 | 233 | 98 | 6% (14) | None | $10,427 |
| 2014 | 203 | 77 | None | None | $11,383 |
| 2013 | 181 | 66 | None | 18% | $10,267 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Metoprolol | 16 | $371 | $23 |
| Furosemide | 20 | $304 | $15 |
| Warfarin | 18 | $225 | $13 |
| Atorvastatin | 14 | $187 | $13 |
2022: 5 drugs
| Atorvastatin | 18 | $316 | $18 |
| Furosemide | 15 | $268 | $18 |
| Tamsulosin | 12 | $237 | $20 |
| Metoprolol | 20 | $164 | $8 |
| Warfarin | 13 | $152 | $12 |
2021: 2 drugs
| Pantoprazole | 17 | $289 | $17 |
| Metoprolol | 15 | $147 | $10 |
2020: 2 drugs
| Atorvastatin | 13 | $211 | $16 |
| Metoprolol | 11 | $107 | $10 |
2019: 6 drugs
| Atorvastatin | 13 | $294 | $23 |
| Furosemide | 15 | $256 | $17 |
| Pantoprazole | 12 | $220 | $18 |
| Warfarin | 16 | $207 | $13 |
| Metoprolol | 12 | $111 | $9 |
| Levofloxacin | 13 | $89 | $7 |
2018: 2 drugs
| Warfarin | 16 | $264 | $17 |
| Furosemide | 19 | $236 | $12 |
2017: 4 drugs
| Warfarin | 17 | $239 | $14 |
| Metoprolol | 19 | $184 | $10 |
| Furosemide | 13 | $177 | $14 |
| Lisinopril | 13 | $150 | $12 |
2016: 5 drugs
| Pantoprazole | 13 | $425 | $33 |
| Warfarin | 32 | $405 | $13 |
| Furosemide | 20 | $273 | $14 |
| Metoprolol | 24 | $226 | $9 |
| Levofloxacin | 12 | $105 | $9 |
2015: 5 drugs
| Cefpodoxime Proxetil | 11 | $903 | $82 |
| Hydralazine | 11 | $405 | $37 |
| Furosemide | 16 | $203 | $13 |
| Warfarin | 14 | $178 | $13 |
| Metoprolol | 11 | $108 | $10 |
2014: 2 drugs
| Warfarin | 13 | $187 | $14 |
| Metoprolol | 16 | $154 | $10 |
2013: 3 drugs
| Cefpodoxime Proxetil | 11 | $783 | $71 |
| Warfarin | 22 | $279 | $13 |
| Metoprolol | 11 | $108 | $10 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Allergan, Inc. · A Multicenter, Randomized, Double-Blind, Dose-Conversion Study To Evaluate the Safety and Efficacy of Hrt W Armour Thyroid Compared To Levothyroxine (T4) in Previously Hypothyroid Participants, Who Are on Euthyroid T4 Replacement · 2020 | Their institution | $169 |
Professional record
- NPI
- 1497834527
- Licence
- CA A62103California A62103: Current · expires 2028-08-31
- Trained
- Hahnemann University College of Medicine, 1995
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A621030
- Taxonomy
- Hospitalist (208M00000X)
- Mailing address
- 1800 Harrison St Fl 7, Oakland, CA, 94612
- NPI first listed
- 2006-11-02
- NPI last updated
- 2021-12-03
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.